MRNS vs. LPTX, TNYA, XBIT, ATOS, ANRO, IVA, NVCT, TARA, IGMS, and INZY
Should you be buying Marinus Pharmaceuticals stock or one of its competitors? The main competitors of Marinus Pharmaceuticals include Leap Therapeutics (LPTX), Tenaya Therapeutics (TNYA), XBiotech (XBIT), Atossa Therapeutics (ATOS), Alto Neuroscience (ANRO), Inventiva (IVA), Nuvectis Pharma (NVCT), Protara Therapeutics (TARA), IGM Biosciences (IGMS), and Inozyme Pharma (INZY). These companies are all part of the "pharmaceutical products" industry.
Marinus Pharmaceuticals vs.
Leap Therapeutics (NASDAQ:LPTX) and Marinus Pharmaceuticals (NASDAQ:MRNS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.
30.5% of Leap Therapeutics shares are owned by institutional investors. Comparatively, 98.8% of Marinus Pharmaceuticals shares are owned by institutional investors. 5.4% of Leap Therapeutics shares are owned by insiders. Comparatively, 5.5% of Marinus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Leap Therapeutics has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500. Comparatively, Marinus Pharmaceuticals has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500.
In the previous week, Leap Therapeutics had 2 more articles in the media than Marinus Pharmaceuticals. MarketBeat recorded 3 mentions for Leap Therapeutics and 1 mentions for Marinus Pharmaceuticals. Leap Therapeutics' average media sentiment score of 0.61 beat Marinus Pharmaceuticals' score of 0.50 indicating that Leap Therapeutics is being referred to more favorably in the media.
Leap Therapeutics currently has a consensus target price of $7.50, indicating a potential upside of 194.12%. Marinus Pharmaceuticals has a consensus target price of $4.79, indicating a potential upside of 786.41%. Given Marinus Pharmaceuticals' higher possible upside, analysts plainly believe Marinus Pharmaceuticals is more favorable than Leap Therapeutics.
Leap Therapeutics has higher earnings, but lower revenue than Marinus Pharmaceuticals. Leap Therapeutics is trading at a lower price-to-earnings ratio than Marinus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Leap Therapeutics has a net margin of 0.00% compared to Marinus Pharmaceuticals' net margin of -446.48%. Leap Therapeutics' return on equity of -116.24% beat Marinus Pharmaceuticals' return on equity.
Marinus Pharmaceuticals received 143 more outperform votes than Leap Therapeutics when rated by MarketBeat users. However, 69.01% of users gave Leap Therapeutics an outperform vote while only 67.13% of users gave Marinus Pharmaceuticals an outperform vote.
Summary
Leap Therapeutics beats Marinus Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get Marinus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Marinus Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:MRNS) was last updated on 1/20/2025 by MarketBeat.com Staff
